{"protocolSection":{"identificationModule":{"nctId":"NCT00092443","orgStudyIdInfo":{"id":"V260-007"},"secondaryIdInfos":[{"id":"2004_077"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Dose Confirmation Efficacy Study (V260-007)","officialTitle":"Study of the Efficacy, Safety, and Immunogenicity of V260 at Expiry"},"statusModule":{"statusVerifiedDate":"2015-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2002-09"},"primaryCompletionDateStruct":{"date":"2004-06","type":"ACTUAL"},"completionDateStruct":{"date":"2004-06","type":"ACTUAL"},"studyFirstSubmitDate":"2004-09-22","studyFirstSubmitQcDate":"2004-09-24","studyFirstPostDateStruct":{"date":"2004-09-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-05-19","resultsFirstSubmitQcDate":"2009-05-19","resultsFirstPostDateStruct":{"date":"2009-07-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-09-11","lastUpdatePostDateStruct":{"date":"2015-09-14","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study was designed to evaluate the safety of the investigational Rotavirus Vaccine and the efficacy to prevent Rotavirus Gastroenteritis.","detailedDescription":"The duration of treatment is 10 months."},"conditionsModule":{"conditions":["Rotavirus Infections"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":1312,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)","type":"EXPERIMENTAL","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)\n\nadministered 28 to 70 days apart.","interventionNames":["Biological: RotaTeq™, rotavirus vaccine, live, oral, pentavalent"]},{"label":"Placebo matching RotaTeq™","type":"PLACEBO_COMPARATOR","description":"Placebo matching RotaTeq™ administered 28 to 70 days apart.","interventionNames":["Biological: Comparator: Placebo matching RotaTeq™"]}],"interventions":[{"type":"BIOLOGICAL","name":"RotaTeq™, rotavirus vaccine, live, oral, pentavalent","description":"Three doses of RotaTeq™ administered 28 to 70 days apart.","armGroupLabels":["RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)"],"otherNames":["V260"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo matching RotaTeq™","description":"Placebo matching RotaTeq™ administered 28 to 70 days apart.","armGroupLabels":["Placebo matching RotaTeq™"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose.","description":"G1, G2, G3, and G4 Serotype Rotavirus Gastroenteritis Cases Occurring at Least 14 Days Postdose 3 Through the First Rotavirus Season Postvaccination in the Per-Protocol Population Using Per-Protocol Case Definition","timeFrame":"At least 14 days following the 3rd vaccination"}],"secondaryOutcomes":[{"measure":"Number of Subjects With ≥3 Fold Rise in Antibody Titer","description":"Induction of postdose 3 rotavirus Serum neutralizing antibody (SNA) response (Number of subjects with ≥3 fold rise in antibody titer)","timeFrame":"14 days following the 3rd vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infants\n\nExclusion Criteria:\n\n* History of abdominal disorders from a birth defect, intussusception, or abdominal surgery\n* Known or suspected problems with immune system\n* Fever at time of immunization\n* Prior administration of a rotavirus vaccine\n* History of known prior rotavirus disease\n* Chronic diarrhea, or failure to thrive","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"17200266","type":"BACKGROUND","citation":"Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM; Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007 Jan;119(1):11-8. doi: 10.1542/peds.2006-2058."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Excluded from the trial before assignment to groups were patients with: history of congenital abdominal\n\ndisorders, intussusception, or abdominal surgery; history of known prior rotavirus disease, chronic diarrhea,\n\nor failure to thrive.","recruitmentDetails":"The study was conducted at 30 sites - 27 in the United States, and 3 in Finland from 24-Sep-2002 (first\n\npatient in) to 11-Feb-2004 (last dose given).\n\nLast subject completed follow-up: 08-Jun-2004.\n\nAll data corrections applied (Frozen File): 07-Sep-2004","groups":[{"id":"FG000","title":"RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination, and followup for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination."},{"id":"FG001","title":"Placebo Matching RotaTeq™","description":"Placebo matching RotaTeq™ administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Subjects who passed all entry criteria and who were randomized in to the study","numSubjects":"651"},{"groupId":"FG001","comment":"Subjects who passed all entry criteria and who were randomized in to the study","numSubjects":"661"}]},{"type":"Vaccinated at Visit 1","achievements":[{"groupId":"FG000","numSubjects":"650"},{"groupId":"FG001","numSubjects":"660"}]},{"type":"Vaccinated at Visit 2","achievements":[{"groupId":"FG000","numSubjects":"618"},{"groupId":"FG001","numSubjects":"627"}]},{"type":"Vaccinated at Visit 3","achievements":[{"groupId":"FG000","numSubjects":"593"},{"groupId":"FG001","numSubjects":"608"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Subjects vaccinated and followed up 42 days after each dose, thru 1st rotavirus season post study","numSubjects":"593"},{"groupId":"FG001","comment":"Subjects vaccinated and followed up 42 days after each dose, thru 1st rotavirus season post study","numSubjects":"607"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"54"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Moved","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"13"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination, and followup for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination."},{"id":"BG001","title":"Placebo Matching RotaTeq™","description":"Placebo matching RotaTeq™ administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"651"},{"groupId":"BG001","value":"661"},{"groupId":"BG002","value":"1312"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"6 to 12 Weeks","categories":[{"measurements":[{"groupId":"BG000","value":"648"},{"groupId":"BG001","value":"658"},{"groupId":"BG002","value":"1306"}]}]},{"title":"Over 12 Weeks","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"304"},{"groupId":"BG001","value":"323"},{"groupId":"BG002","value":"627"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"347"},{"groupId":"BG001","value":"338"},{"groupId":"BG002","value":"685"}]}]}]},{"title":"Race/Ethnicity","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"525"},{"groupId":"BG001","value":"540"},{"groupId":"BG002","value":"1065"}]}]},{"title":"Hispanic American","categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"156"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"44"}]}]},{"title":"Multi-Racial","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"32"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose.","description":"G1, G2, G3, and G4 Serotype Rotavirus Gastroenteritis Cases Occurring at Least 14 Days Postdose 3 Through the First Rotavirus Season Postvaccination in the Per-Protocol Population Using Per-Protocol Case Definition","populationDescription":"Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., unevaluable due to wild-type rotavirus-positive stool antigen Enzyme immunoassay (EIA) prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"At least 14 days following the 3rd vaccination","groups":[{"id":"OG000","title":"RotaTeq™ at Expiry Potency (≈1.1 x 107 IU/Dose)","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination."},{"id":"OG001","title":"Placebo Matching RotaTeq™","description":"Placebo matching RotaTeq™ administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination and follow-up for AGEs through the first rotavirus season post vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"551"},{"groupId":"OG001","value":"564"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"54"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Exact Binomial Test","paramType":"Efficacy = 1-Relative Risk","paramValue":"72.5","ciPctValue":"95","ciLowerLimit":"50.6","ciUpperLimit":"85.6","estimateComment":"Efficacy = 1-RR, expressed as a percentage; the RR is the incidence in the vaccine group / the incidence in the placebo group."}]},{"type":"SECONDARY","title":"Number of Subjects With ≥3 Fold Rise in Antibody Titer","description":"Induction of postdose 3 rotavirus Serum neutralizing antibody (SNA) response (Number of subjects with ≥3 fold rise in antibody titer)","populationDescription":"Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., unevaluable due to wild-type rotavirus-positive stool antigen EIA prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"14 days following the 3rd vaccination","groups":[{"id":"OG000","title":"RotaTeq™ at Expiry Potency (SNA - G1)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG001","title":"RotaTeq™ at Expiry Potency (SNA - G2)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG002","title":"RotaTeq™ at Expiry Potency (SNA - G3)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG003","title":"RotaTeq™ at Expiry Potency (SNA - G4)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG004","title":"RotaTeq™ at Expiry Potency (SNA - P1A)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG005","title":"Placebo Matching RotaTeq™ (SNA - G1)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG006","title":"Placebo Matching RotaTeq™ (SNA - G2)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG007","title":"Placebo Matching RotaTeq™ (SNA - G3)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG008","title":"Placebo Matching RotaTeq™ (SNA - G4)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."},{"id":"OG009","title":"Placebo Matching RotaTeq™ (SNA - P1A)","description":"Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"67"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"61"},{"groupId":"OG005","value":"73"},{"groupId":"OG006","value":"70"},{"groupId":"OG007","value":"75"},{"groupId":"OG008","value":"70"},{"groupId":"OG009","value":"69"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"56.7","ciPctValue":"95","ciLowerLimit":"44.0","ciUpperLimit":"66.8"},{"groupIds":["OG005"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"2.7","ciPctValue":"95","ciLowerLimit":"0.3","ciUpperLimit":"9.5"},{"groupIds":["OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"14.5","ciPctValue":"95","ciLowerLimit":"6.9","ciUpperLimit":"25.8"},{"groupIds":["OG006"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"0.0","ciPctValue":"95","ciLowerLimit":"0.0","ciUpperLimit":"5.1"},{"groupIds":["OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"9.0","ciPctValue":"95","ciLowerLimit":"3.4","ciUpperLimit":"18.5"},{"groupIds":["OG007"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"0.0","ciPctValue":"95","ciLowerLimit":"0.0","ciUpperLimit":"4.8"},{"groupIds":["OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"39.7","ciPctValue":"95","ciLowerLimit":"27.6","ciUpperLimit":"52.8"},{"groupIds":["OG008"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"1.4","ciPctValue":"95","ciLowerLimit":"0.0","ciUpperLimit":"7.7"},{"groupIds":["OG004"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"24.6","ciPctValue":"95","ciLowerLimit":"14.5","ciUpperLimit":"37.3"},{"groupIds":["OG009"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent of Participants","paramValue":"2.9","ciPctValue":"95","ciLowerLimit":"0.4","ciUpperLimit":"10.1"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)","description":"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination.","seriousNumAffected":21,"seriousNumAtRisk":649,"otherNumAffected":558,"otherNumAtRisk":649},{"id":"EG001","title":"Placebo Matching RotaTeq™","description":"Placebo matching RotaTeq™ administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination and follow-up for AGEs through the first rotavirus season post vaccination.","seriousNumAffected":28,"seriousNumAtRisk":658,"otherNumAffected":565,"otherNumAtRisk":658}],"seriousEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Perirectal abscess","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Sudden infant death syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Milk allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":649},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":658}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Croup infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Gastroenteritis rotavirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":658}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Pertussis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":658}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":658}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":658}]},{"term":"Spinal cord neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Cerebral cyst","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":649},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":658}]},{"term":"Dermatitis atopic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":649},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":658}]}],"otherEvents":[{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":50,"numAtRisk":649},{"groupId":"EG001","numEvents":53,"numAffected":46,"numAtRisk":658}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":35,"numAtRisk":649},{"groupId":"EG001","numEvents":38,"numAffected":34,"numAtRisk":658}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":160,"numAffected":103,"numAtRisk":649},{"groupId":"EG001","numEvents":177,"numAffected":110,"numAtRisk":658}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":72,"numAffected":52,"numAtRisk":649},{"groupId":"EG001","numEvents":78,"numAffected":49,"numAtRisk":658}]},{"term":"Regurgitation of food","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":44,"numAtRisk":649},{"groupId":"EG001","numEvents":55,"numAffected":41,"numAtRisk":658}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":112,"numAffected":81,"numAtRisk":649},{"groupId":"EG001","numEvents":116,"numAffected":77,"numAtRisk":658}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":61,"numAtRisk":649},{"groupId":"EG001","numEvents":81,"numAffected":62,"numAtRisk":658}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":450,"numAffected":283,"numAtRisk":649},{"groupId":"EG001","numEvents":438,"numAffected":265,"numAtRisk":658}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":103,"numAffected":91,"numAtRisk":649},{"groupId":"EG001","numEvents":132,"numAffected":106,"numAtRisk":658}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":143,"numAffected":119,"numAtRisk":649},{"groupId":"EG001","numEvents":144,"numAffected":111,"numAtRisk":658}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":41,"numAtRisk":649},{"groupId":"EG001","numEvents":32,"numAffected":28,"numAtRisk":658}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":84,"numAffected":69,"numAtRisk":649},{"groupId":"EG001","numEvents":110,"numAffected":81,"numAtRisk":658}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":192,"numAffected":150,"numAtRisk":649},{"groupId":"EG001","numEvents":172,"numAffected":143,"numAtRisk":658}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":145,"numAffected":102,"numAtRisk":649},{"groupId":"EG001","numEvents":145,"numAffected":99,"numAtRisk":658}]},{"term":"Crying","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":53,"numAtRisk":649},{"groupId":"EG001","numEvents":79,"numAffected":52,"numAtRisk":658}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":248,"numAffected":155,"numAtRisk":649},{"groupId":"EG001","numEvents":299,"numAffected":172,"numAtRisk":658}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":111,"numAffected":95,"numAtRisk":649},{"groupId":"EG001","numEvents":106,"numAffected":90,"numAtRisk":658}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":39,"numAtRisk":649},{"groupId":"EG001","numEvents":68,"numAffected":53,"numAtRisk":658}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":73,"numAffected":59,"numAtRisk":649},{"groupId":"EG001","numEvents":50,"numAffected":42,"numAtRisk":658}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Safety has been reported in the literature."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"Vice President, Late Stage Development Group Leader","organization":"Merck Sharp & Dohme Corp","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["United States"]},"conditionBrowseModule":{"meshes":[{"id":"D012400","term":"Rotavirus Infections"}],"ancestors":[{"id":"D012088","term":"Reoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"C492535","term":"RotaTeq"},{"id":"D022243","term":"Rotavirus Vaccines"}],"ancestors":[{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}